Prime Medicine Inc PRME

$3.85 +0.38 (10.95%)

Valuation

Market cap
629,378,000
Revenue TTM
$4,630,000
Net income TTM
$-201,140,000
PE ratio
0.00
Forward PE
—
Profit margin
-4,344.28%
Debt to equity
0.00

Trading

Volume
3,541,556
Avg volume
3,665,224
Day's range
$3.49 – $3.87
Shares out
181,377,000
Stochastic %K
39%
Beta
2.37
Analysts
Strong Sell
Price target
$7.02

Price

Company profile

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in...

Show more

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration and license agreement with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 465 0013
Website
https://primemedicine.com
Address
60 First Street, Cambridge, United States

Latest news

Stocktwits

topstockalerts Oct 19, 5:41 PM
$PRME I didn’t think this had this kind of stamina.
0 replies
srost002 Oct 19, 4:40 PM
$PRME blast through 4. COME ON
0 replies
FredGS Oct 19, 2:29 PM
$PRME We need to hit that escape velocity!
0 replies
Toro_of_Ga Oct 19, 2:01 PM
$PRME I purchased another 2000 shares, yes I did, I'm the man.
1 replies
Toro_of_Ga Oct 19, 1:59 PM
$PRME
0 replies
BIOTECH_GURU Oct 19, 3:00 AM
$PRME
0 replies
quark_n_jaguar Oct 18, 2:43 PM
$PRME Not to restate the obvious, but the biggest worry for PRME is not the tech or pipelines, it’s the bond markets and the resulting forecast adjustments, high interest rates to raise funds, and uncertainty in keeping their pipelines funded. They should be better capitalized than where they are. So the better figure something if/before the bond market turns worse - its real - Caribou fell ‘cos of that, but it was made worse by their more uncertain pipelines.
0 replies
R8NGER Oct 18, 12:31 PM
$PRME This is a good article explaining the good the bad the ugly and a possible short squeeze. Read it all the way through as she explains what big dark pool money is doing to pin the stock as well as the dilution risk. https://www.annacoulling.com/stock-trader-tips/the-forensics-of-prime-medicine-deconstructing-the-volume-anomalies-and-corporate-plumbing-of-prme/
1 replies